Elacestrant
Menarini
['elacestrant', 'bcsm']
 duration of prior cdk4/6 inhibitor [treatment] in the metastatic setting was shown to be a predictor of efficacy in patients with esr1 mutations receiving elacestrant," said virginia g. kaklamani, md. #bcsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.